Evidence map›Paper›PMID 26851233›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

DNA Methylation of BDNF Gene in Schizophrenia.

Ümit Sertan Çöpoğlu, Mehri Igci, Esra Bozgeyik, M Hanifi Kokaçya, Yusuf Ziya İğci, Recep Dokuyucu, Mustafa Ari, Haluk A Savaş

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Glioma in Schizophrenia: Is the Risk Higher or Lower?Frontiers in cellular neuroscience · 2018
    Review
  5. Article
  6. Olig2 Silence Ameliorates Cuprizone-Induced Schizophrenia-Like Symptoms in Mice.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ümit Sertan ÇöpoğluDepartment of Psychiatry, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Mehri IgciDepartment Medical Biology, School of Medicine, Gaziantep University, Gaziantep, Turkey.
Esra BozgeyikDepartment Medical Biology, School of Medicine, Gaziantep University, Gaziantep, Turkey.
M Hanifi KokaçyaDepartment of Psychiatry, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Yusuf Ziya İğciDepartment Medical Biology, School of Medicine, Gaziantep University, Gaziantep, Turkey.
Recep DokuyucuDepartment of Physiology, School of Medicine, Mustafa Kemal University, Hatay, Turkey.
Mustafa AriDepartment of Physiology, Mustafa Kemal University, School of Medicine, Hatay, Turkey.
Haluk A SavaşDepartment Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey.
Gaziantep University · TRMustafa Kemal University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Although genetic factors are risk factors for schizophrenia, some environmental factors are thought to be required for the manifestation of disease. Epigenetic mechanisms regulate gene functions without causing a change in the nucleotide sequence of DNA. Brain-derived neurotrophic factor (BDNF) is a neurotrophin that regulates synaptic transmission and plasticity. It has been suggested that BDNF may play a role in the pathophysiology of schizophrenia. It is established that methylation status of the BDNF gene is associated with fear learning, memory, and stressful social interactions. In this study, we aimed to investigate the DNA methylation status of BDNF gene in patients with schizophrenia. MATERIAL AND METHODS The study included 49 patients (33 male and 16 female) with schizophrenia and 65 unrelated healthy controls (46 male and 19 female). Determination of methylation pattern of CpG islands was based on the principle that bisulfite treatment of DNA results in conversion of unmethylated cytosine residues into uracil, whereas methylated cytosine residues remain unmodified. Methylation-specific PCR was performed with primers specific for either methylated or unmethylated DNA. RESULTS There was no significant difference in methylated or un-methylated status for BDNF promoters between schizophrenia patients and controls. The mean duration of illness was significantly lower in the hemi-methylated group compared to the non-methylated group for BDNF gene CpG island-1 in schizophrenia patients. CONCLUSIONS Although there were no differences in BDNF gene methylation status between schizophrenia patients and healthy controls, there was an association between duration of illness and DNA methylation.

Indexed as

DNA MethylationAdultBrain-Derived Neurotrophic FactorCase-Control StudiesCpG IslandsDNA PrimersEpigenomicsFemaleHumansMalePolymerase Chain ReactionPromoter Regions, GeneticSchizophreniaBDNF protein, humanBrain-Derived Neurotrophic FactorDNA Primers

Identifiers

PMID26851233
PMCPMC4749043
OpenAlexW2259203675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.